Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.

In October 2010, Biocon, an Indian pharmaceutical company, and Pfizer partnered to develop and market biosimilar insulin analogs (see NewNowNext in diaTribe #26). A...

Recently, we were excited to hear that Sanofi/AgaMatrix have received FDA clearance for the iBGStar , the first blood glucose monitor that connects directly to an Apple...

Earlier in April, Biodel management updated the timeline for the development of its ultra-rapid-acting insulin candidates. As a reminder, in October 2010 the company's...

Diabetes on stage: Jim Hirsch tells us about Robbie McCauley’s powerful one-woman production, “Sugar."

The Diabetes Barometer

April has been quite a busy month for Medtronic with the launch of new CareLink software that is finally Mac-compatible and the introduction of the greatly anticipated...

While the pharmaceutical industry continues to offer new products, it has been over two years since the FDA has approved a diabetes medication with a completely novel...

Lessons from TCOYD, Santa Clara.

Kelly reflects on 25 years with diabetes, and her hopes for future breakthroughs…

If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...

In late November, the Centers for Medicare and Medicaid Services (the federal agency that administers the two public insurance programs) announced that Medicare would...

diaTribe 's take on the recent New England Journal of Medicine's piece on weight gain - and loss!

This article presciently reviews what we know about tight control - how many people with diabetes in the U.S. are getting there, and what it means for complications...

Several months after an FDA advisory committee delivered an overwhelmingly positive vote (20-2) in favor of approving Vivus’ Qnexa for the treatment of obesity, the...

Insulet recently announced that its second-generation OmniPod had received approval in Europe. Compared to the first-generation OmniPod, the new pod is approximately 40...

The "Resource Guide" is special supplement to Diabetes Forecast that comes out every year and features comments on and comparisons of all the available products for...

How can kids with diabetes most enjoy Halloween? Jim Hirsch shares his thoughts.

Although insulin pens don't often grab headlines as much as other diabetes devices, we were glad to hear news about Novo Nordisk’s FlexTouch pen earlier this summer. The...

As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...